Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone

International Journal of Psychiatry in Clinical Practice

Volumn 12, Issue 3, 2008, Pages 180-186

  Wang, Yu Ting ^a,d   Chiu, Nan Ying ^c   Jou, Shaw Hwa ^c   Kuang Yang, Yen ^a,b   Hui Lee, I ^a,b   Wang, Ching Cheng ^c   Ching Chen, Kao ^a,b   Liao, Yi Cheng ^c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d ST MARTIN DE PORRES HOSPITAL   (Taiwan)

Author keywords

Amisulpride; Cognitive function; Hyperprolactinemia

Indexed keywords

AMISULPRIDE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; MEMORY; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT;

EID: 48249129672     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701805727     Document Type: Article

References (43)

1. Coulouvrat C, Dondey-Nouvel L, Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999;14(4):209-18.
2. Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280(1):73-82.
3. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280(1):83-97.
4. Moller HJ. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatr Scand Suppl 2000;400:17-22.
5. Rein W, Coulouvrat C, Dondey-Nouvel L, Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short- and long-term use. Acta Psychiatri Scand Suppl 2000;400:23-7.
6. Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154 (6):799-804.
7. Liddle PF, Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand Suppl 2000;400:11-16.
8. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berlin) 2000;148(1):3-15.
9. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 2004;11(3):343-58.
10. Tollefson GD, Sanger TM, Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res 1999;35(Suppl):S13-21.
11. Tollefson GD, Andersen SW, Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 1999;60(Suppl 5):23-29; discussion 30.
12. Haddad PM, Wieck A, Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314.
13. Markianos M, Hatzimanolis J, Lykouras L, Markianos M, Hatzimanolis J, Lykouras L. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology 1999;143(3):270-2.
14. Markianos M, Hatzimanolis J, Lykouras L, Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 1999;9(6):533-6.
15. Kern RS, Green MF, Marshall BD Jr, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 1999;25(2):223-32.
16. Matsui M, Sumiyoshi T, Abe R, Kato K, Yuuki H, Kurachi M. Impairment of story memory organization in patients with schizophrenia. Psychiatry Clin Neurosci 2007;61(4):437-40.
17. Bruder GE, Wexler BE, Sage MM, Gil RB, Gorman JM. Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res 2004;68(2-3):137-47.
18. Guy W. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology (revised). Rockville, MD: National Institute of Mental Health; 1976. p 217-21.
19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-76.
20. Barnes TR, Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
21. Anonymous. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 1988;24(4):781-3.
22. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76(2-3):247-65.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
24. Chen KC, Yang YK, Lee IH, Yeh TL, Lu R-B, Chen PS. Sexual dysfunction and physicians' perception in medicated patients with major depression in Taiwan. Depression Anxiety 2007;in press.
25. Yao G, Chung CW, Yu CF, et al. Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formosan Med Assoc 2002;101(5):342-51.
26. Montgomery SA, Smeyatsky N, de Ruiter M, et al. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl 1985;320:38-42.
27. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88(2):107-17.
28. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002;27(6):1071-81.
29. Colonna L, Saleem P, Dondey-Nouvel L, et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacology 2000;15(1):13-22.
30. Hwang TJ, Lee SM, Sun HJ, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formosan Med Assoc 2003;102(1):30-6.
31. Loo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22.
32. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36(1):143-64.
33. Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21(5):479-83.
34. Poyurovsky M, Koren D, Gonopolsky I, et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 2003;13(2):123-8.
35. Umbricht D, Vollenweider FX, Schmid L, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 2003;28(1):170-81.
36. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 2004;114(6):593-611.
37. Wagner M, Quednow BB, Westheide J, et al. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005;30(2):381-90.
38. Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev 1999;23(8):1111-25.
39. Tyson PJ, Laws KR, Flowers KA, Tyson A, Mortimer AM. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry Clin Neurosci 2006;60(4):473-9.
40. Liu SK, Hwu HG, Chen WJ, Liu SK, Hwu HG, Chen WJ. Clinical symptom dimensions and deficits on the Continuous Performance Test in schizophrenia. Schizophr Res 1997;25(3):211-19.
41. Vaiva G, Thomas P, Llorca PM, et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res 2002;115(1-2):37-48.
42. Liu SK, Chiu CH, Chang CJ, et al. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. Am J Psychiatry 2002;159(6):975-82.
43. Zalla T, Joyce C, Szoke A, et al. Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Res 2004;121(3):207-17.